Skip to main content
OpenTrials

Clinical trial condition

NASH - Nonalcoholic Steatohepatitis

Explore clinical trials studying NASH - Nonalcoholic Steatohepatitis. Study availability and eligibility vary by location and protocol.

78 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

NASH - Nonalcoholic Steatohepatitis trial results

Completed

Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome"

NCT04616664

Conditions
Body Weight, Digestive System Diseases, Fatty Liver, +15 more
Locations
  • Chu Amiens Picardie Amiens, France
  • CH ARRAS Arras, France
  • CH de Douai Douai, France
  • CH LENS Lens, France
View Trial Details
Completed

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

NCT03912532

Conditions
Digestive System Diseases, Fatty Liver, Liver Diseases, +2 more
Locations
  • NGM Clinical Study Site Chandler, Arizona, United States
  • NGM Clinical Study Site 814 Tucson, Arizona, United States
  • NGM Clinical Study Site 816 Tucson, Arizona, United States
  • NGM Clinical Study Site North Little Rock, Arkansas, United States
View all 37 locations
View Trial Details
Completed

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04767529

Conditions
Digestive System Diseases, Fatty Liver, Liver Diseases, +2 more
Locations
  • Akero Clinical Study Site Chandler, Arizona, United States
  • Akero Clinical Study Site Glendale, Arizona, United States
  • Akero Clinical Study Site Tucson, Arizona, United States
  • Akero Clinical Study Site North Little Rock, Arkansas, United States
View all 55 locations
View Trial Details
Completed

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NCT05415722

Conditions
Digestive System Diseases, Fatty Liver, Liver Diseases, +2 more
Locations
  • Site 1017: The Institute for Liver Health dba Arizona Liver Health Chandler, Arizona, United States
  • Site 1018: Arizona Liver Health Tucson, Arizona, United States
  • Site 1004 Southern California Research Center Coronado, California, United States
  • Site 1061 Velocity Clinical Research, Gardena Gardena, California, United States
View all 35 locations
View Trial Details
Completed

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

NCT04685993

Conditions
Digestive System Diseases, Fatty Liver, Liver Diseases, +2 more
Locations
  • Clinical Trials Research Roseville, California, United States
  • Sensible Healthcare, LLC Ocoee, Florida, United States
  • Jubilee Clinical Research, Inc. Las Vegas, Nevada, United States
  • R&H Clinical Research Katy, Texas, United States
View Trial Details
Completed

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

NCT05232071

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Digestive System Diseases, +8 more
Locations
  • Birmingham Digestive Health Research Homewood, Alabama, United States
  • Institute for Liver Health dba Arizona Liver Health Chandler, Arizona, United States
  • ARcare Center for Clinical Research Conway, Arkansas, United States
  • ARcare Center for Clinical Research Little Rock, Arkansas, United States
View all 42 locations
View Trial Details

Related conditions